欧康维视生物-B现涨逾6% 氟轻松玻璃体植入剂获准于海南博鳌进行真实世界研究

新浪港股
May 19, 2025
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  欧康维视生物-B(01477)盘中涨超8%,截至发稿,股价上涨5.78%,现报5.67港元,成交额1887.68万港元。

  近日,欧康维视生物-B发布公告,该集团产品OT-703(ILUVIEN®,氟轻松玻璃体植入剂)(是一款可注射的、非生物降解的氟轻松玻璃体植入剂,用于治疗糖尿病性黄斑水肿(DME))最近已获准于海南省博鳌乐城国际医疗旅游先行区进行真实世界研究。

  OT-703(即190微克氟轻松玻璃体内植入剂(0.19毫克))是一款可注射的、非生物降解的氟轻松玻璃体植入剂,通过于眼部连续使用最多36个月的微量非专有皮质类固醇醋酸氟轻松(FAc)治疗DME。其已获得美国食品药品监督管理局(FDA)的监管批准,并以商号‘ILUVIEN®’上市。OT-703是FDA批准的唯一一款缓释长达3年的治疗DME的皮质类固醇眼内植入剂。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10